Regulus Cost Of Revenue vs Non Operating Income Net Other Analysis

RGLS Stock

USD 1.61 0.03 1.83%

Regulus Therapeutics financial indicator trend analysis is much more than just breaking down Regulus Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Regulus Therapeutics is a good investment. Please check the relationship between Regulus Therapeutics Cost Of Revenue and its Non Operating Income Net Other accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regulus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Regulus Stock please use our How to Invest in Regulus Therapeutics guide.

Cost Of Revenue vs Non Operating Income Net Other

Cost Of Revenue vs Non Operating Income Net Other Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Regulus Therapeutics Cost Of Revenue account and Non Operating Income Net Other. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Regulus Therapeutics' Cost Of Revenue and Non Operating Income Net Other is -0.28. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Non Operating Income Net Other in the same time period over historical financial statements of Regulus Therapeutics, assuming nothing else is changed. The correlation between historical values of Regulus Therapeutics' Cost Of Revenue and Non Operating Income Net Other is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Regulus Therapeutics are associated (or correlated) with its Non Operating Income Net Other. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Operating Income Net Other has no effect on the direction of Cost Of Revenue i.e., Regulus Therapeutics' Cost Of Revenue and Non Operating Income Net Other go up and down completely randomly.

Correlation Coefficient

-0.28

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Cost Of Revenue

Cost of Revenue is found on Regulus Therapeutics income statement and represents the costs associated with goods and services Regulus Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Non Operating Income Net Other

Most indicators from Regulus Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Regulus Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regulus Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more information on how to buy Regulus Stock please use our How to Invest in Regulus Therapeutics guide.At this time, Regulus Therapeutics' Tax Provision is comparatively stable compared to the past year. Issuance Of Capital Stock is likely to gain to about 18 M in 2024, whereas Selling General Administrative is likely to drop slightly above 9.4 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Expense	855K	688K	604K	1.1M
Depreciation And Amortization	459K	122K	227K	215.7K

Interest Expense Depreciation And Amortization

Regulus Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Accounts Payable	Cash	Other Assets	Long Term Debt	Common Stock Shares Outstanding	Short Term Investments	Other Current Assets	Total Liab	Preferred Stock Total Equity	Intangible Assets	Property Plant Equipment	Short Long Term Debt Total	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Non Current Liabilities Total	Other Stockholder Equity
Total Assets		-0.55	-0.32	0.9	0.07	0.36	0.64	0.78	-0.02	-0.4	0.95	0.59	0.1	-0.23	0.71	0.23	0.66	0.23	0.07	-0.55	0.55	0.4	-0.12	0.97	0.13	-0.29
Other Current Liab	-0.55		0.23	-0.44	0.15	0.05	0.07	-0.78	0.24	0.15	-0.5	0.04	-0.17	0.15	-0.29	0.14	-0.36	0.13	-0.07	-0.13	-0.24	-0.03	-0.15	-0.61	-0.1	0.1
Total Current Liabilities	-0.32	0.23		-0.4	0.13	0.5	-0.48	-0.15	-0.21	-0.23	-0.25	-0.18	0.21	-0.02	-0.02	0.49	0.3	0.48	-0.12	0.53	-0.18	0.43	-0.2	-0.38	-0.13	0.08
Total Stockholder Equity	0.9	-0.44	-0.4		-0.27	0.23	0.72	0.66	-0.2	-0.15	0.78	0.62	-0.33	-0.53	0.4	0.09	0.48	0.09	-0.24	-0.68	0.21	0.22	0.07	0.88	-0.25	0.08
Other Liab	0.07	0.15	0.13	-0.27		0.15	-0.16	-0.02	0.56	-0.55	0.24	-0.13	0.81	0.75	0.67	0.23	0.2	0.22	0.86	0.24	0.79	0.26	-0.51	0.07	0.88	-0.88
Accounts Payable	0.36	0.05	0.5	0.23	0.15		0.19	0.32	0.06	-0.46	0.41	0.48	0.28	-0.16	0.45	0.87	0.74	0.87	-0.25	-0.07	0.12	0.89	-0.32	0.28	0.04	0.0
Cash	0.64	0.07	-0.48	0.72	-0.16	0.19		0.28	0.16	-0.21	0.58	0.73	-0.25	-0.34	0.37	0.15	0.34	0.15	-0.16	-0.98	0.25	0.22	-0.16	0.61	-0.15	-0.03
Other Assets	0.78	-0.78	-0.15	0.66	-0.02	0.32	0.28		-0.23	-0.39	0.78	0.2	0.19	-0.18	0.55	0.2	0.69	0.21	0.01	-0.17	0.4	0.39	-0.04	0.8	0.14	-0.18
Long Term Debt	-0.02	0.24	-0.21	-0.2	0.56	0.06	0.16	-0.23		-0.21	0.04	-0.05	0.41	0.27	0.34	0.24	-0.07	0.23	0.46	-0.1	0.41	0.22	-0.27	-0.02	0.49	-0.48
Common Stock Shares Outstanding	-0.4	0.15	-0.23	-0.15	-0.55	-0.46	-0.21	-0.39	-0.21		-0.53	-0.24	-0.63	-0.26	-0.78	-0.32	-0.75	-0.3	-0.52	0.11	-0.72	-0.41	0.88	-0.45	-0.5	0.58
Short Term Investments	0.95	-0.5	-0.25	0.78	0.24	0.41	0.58	0.78	0.04	-0.53		0.57	0.29	-0.06	0.84	0.28	0.74	0.28	0.22	-0.49	0.69	0.46	-0.18	0.94	0.29	-0.44
Other Current Assets	0.59	0.04	-0.18	0.62	-0.13	0.48	0.73	0.2	-0.05	-0.24	0.57		-0.12	-0.24	0.39	0.4	0.51	0.41	-0.26	-0.72	0.16	0.44	-0.16	0.51	-0.13	0.05
Total Liab	0.1	-0.17	0.21	-0.33	0.81	0.28	-0.25	0.19	0.41	-0.63	0.29	-0.12		0.73	0.68	0.3	0.41	0.3	0.72	0.34	0.74	0.36	-0.51	0.13	0.87	-0.81
Preferred Stock Total Equity	-0.23	0.15	-0.02	-0.53	0.75	-0.16	-0.34	-0.18	0.27	-0.26	-0.06	-0.24	0.73		0.29	-0.14	-0.09	-0.15	0.73	0.36	0.56	-0.14	-0.3	-0.22	0.88	-0.75
Intangible Assets	0.71	-0.29	-0.02	0.4	0.67	0.45	0.37	0.55	0.34	-0.78	0.84	0.39	0.68	0.29		0.4	0.74	0.39	0.59	-0.26	0.92	0.54	-0.52	0.71	0.63	-0.77
Property Plant Equipment	0.23	0.14	0.49	0.09	0.23	0.87	0.15	0.2	0.24	-0.32	0.28	0.4	0.3	-0.14	0.4		0.6	1.0	-0.19	-0.05	0.08	0.98	-0.23	0.13	0.06	-0.03
Short Long Term Debt Total	0.66	-0.36	0.3	0.48	0.2	0.74	0.34	0.69	-0.07	-0.75	0.74	0.51	0.41	-0.09	0.74	0.6		0.6	0.02	-0.21	0.48	0.72	-0.47	0.65	0.18	-0.26
Property Plant And Equipment Net	0.23	0.13	0.48	0.09	0.22	0.87	0.15	0.21	0.23	-0.3	0.28	0.41	0.3	-0.15	0.39	1.0	0.6		-0.21	-0.05	0.07	0.98	-0.22	0.14	0.04	-0.01
Current Deferred Revenue	0.07	-0.07	-0.12	-0.24	0.86	-0.25	-0.16	0.01	0.46	-0.52	0.22	-0.26	0.72	0.73	0.59	-0.19	0.02	-0.21		0.19	0.83	-0.13	-0.48	0.13	0.83	-0.91
Net Debt	-0.55	-0.13	0.53	-0.68	0.24	-0.07	-0.98	-0.17	-0.1	0.11	-0.49	-0.72	0.34	0.36	-0.26	-0.05	-0.21	-0.05	0.19		-0.16	-0.1	0.11	-0.53	0.23	-0.04
Retained Earnings	0.55	-0.24	-0.18	0.21	0.79	0.12	0.25	0.4	0.41	-0.72	0.69	0.16	0.74	0.56	0.92	0.08	0.48	0.07	0.83	-0.16		0.22	-0.52	0.58	0.81	-0.93
Non Current Assets Total	0.4	-0.03	0.43	0.22	0.26	0.89	0.22	0.39	0.22	-0.41	0.46	0.44	0.36	-0.14	0.54	0.98	0.72	0.98	-0.13	-0.1	0.22		-0.25	0.31	0.12	-0.13
Non Currrent Assets Other	-0.12	-0.15	-0.2	0.07	-0.51	-0.32	-0.16	-0.04	-0.27	0.88	-0.18	-0.16	-0.51	-0.3	-0.52	-0.23	-0.47	-0.22	-0.48	0.11	-0.52	-0.25		-0.17	-0.42	0.44
Cash And Short Term Investments	0.97	-0.61	-0.38	0.88	0.07	0.28	0.61	0.8	-0.02	-0.45	0.94	0.51	0.13	-0.22	0.71	0.13	0.65	0.14	0.13	-0.53	0.58	0.31	-0.17		0.15	-0.29
Non Current Liabilities Total	0.13	-0.1	-0.13	-0.25	0.88	0.04	-0.15	0.14	0.49	-0.5	0.29	-0.13	0.87	0.88	0.63	0.06	0.18	0.04	0.83	0.23	0.81	0.12	-0.42	0.15		-0.9
Other Stockholder Equity	-0.29	0.1	0.08	0.08	-0.88	0.0	-0.03	-0.18	-0.48	0.58	-0.44	0.05	-0.81	-0.75	-0.77	-0.03	-0.26	-0.01	-0.91	-0.04	-0.93	-0.13	0.44	-0.29	-0.9

Click cells to compare fundamentals

Regulus Therapeutics Account Relationship Matchups

Regulus Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	42.1M	37.6M	68.5M	46.7M	30.8M	61.4M
Other Current Liab	5.6M	6.4M	4.9M	7.0M	7.0M	4.8M
Total Current Liabilities	21.6M	11.6M	5.2M	11.7M	8.5M	15.5M
Total Stockholder Equity	20.0M	26.0M	55.0M	33.3M	21.2M	35.4M
Other Liab	10.0M	7.1M	468K	1.2M	1.1M	1.0M
Accounts Payable	1.3M	535K	285K	175K	204K	193.8K
Cash	34.1M	31.1M	60.4M	24.2M	23.8M	35.1M
Other Assets	0.0	24K	291K	1.0	0.9	0.86
Common Stock Shares Outstanding	1.7M	3.5M	8.6M	15.3M	19.0M	19.9M
Other Current Assets	1.2M	1.8M	1.8M	1.9M	1.4M	1.3M
Total Liab	22.1M	11.6M	13.5M	13.4M	9.6M	9.1M
Intangible Assets	266K	125K	83K	62K	33K	31.4K
Property Plant Equipment	921K	725K	2.8M	2.6M	2.3M	3.6M
Short Long Term Debt Total	14.7M	4.7M	7.1M	6.3M	2.4M	2.3M
Property Plant And Equipment Net	921K	472K	2.8M	2.6M	2.5M	3.6M
Current Deferred Revenue	2.6M	6K	3.4M	(589K)	(530.1K)	(503.6K)
Net Debt	(19.5M)	(26.4M)	(53.3M)	(17.9M)	(21.4M)	(22.4M)
Retained Earnings	(411.3M)	(427.0M)	(454.9M)	(483.2M)	(513.2M)	(487.6M)
Non Current Assets Total	1.7M	874K	3.2M	2.6M	2.6M	4.4M
Non Currrent Assets Other	487K	277K	291K	3.0M	3.5M	3.6M
Cash And Short Term Investments	34.1M	31.1M	60.4M	39.2M	23.8M	22.6M
Liabilities And Stockholders Equity	42.1M	37.6M	68.5M	46.7M	30.8M	29.2M
Non Current Liabilities Total	468K	5.2M	8.3M	1.8M	1.1M	1.0M
Other Stockholder Equity	431.3M	453.0M	509.7M	516.5M	534.4M	377.9M
Property Plant And Equipment Gross	921K	472K	7.2M	7.0M	6.8M	6.0M
Total Current Assets	40.4M	36.7M	65.2M	44.1M	28.2M	26.8M
Accumulated Other Comprehensive Income	(134K)	(9.9M)	(4.4M)	(12K)	(1K)	(1.1K)
Short Term Debt	14.6M	4.7M	589K	4.5M	1.3M	1.3M
Net Tangible Assets	19.7M	25.9M	28.9M	33.2M	29.9M	43.5M
Common Stock Total Equity	104K	9K	21K	67K	77.1K	53.0K
Retained Earnings Total Equity	(345.9M)	(392.7M)	(411.3M)	(427.0M)	(384.3M)	(403.6M)
Capital Surpluse	381.1M	386.9M	431.3M	453.0M	521.0M	356.5M
Inventory	4.2M	3.9M	3.3M	3.0K	3.0M	3.2M
Non Current Liabilities Other	0.0	7.1M	468K	1.2M	1.4M	1.9M
Common Stock	21K	67K	146K	17K	20K	19K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Regulus Stock Analysis

When running Regulus Therapeutics' price analysis, check to measure Regulus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regulus Therapeutics is operating at the current time. Most of Regulus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Regulus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regulus Therapeutics' price. Additionally, you may evaluate how the addition of Regulus Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC